Table 2.
Treatment and tumor characteristics for all included patients and PSM pairs.
| Characteristics | All Included Patients | PSM Patients | ||||
|---|---|---|---|---|---|---|
| Open | VATS | p-Value | Open | VATS | p-Value | |
| Induction therapy, n (%) | ||||||
| Platinum doublet therapy only |
90 (70.3) | 48 (62.4) | 0.282 | 39 (60.9) | 38(59.4) | 1 |
| Platinum doublet therapy + Immunotherapy |
5 (3.9) | 3 (3.9) | 1 | 5 (7.8) | 3 (4.7) | 0.717 |
| Chemoradiotherapy | 33 (25.8) | 26 (33.7) | 0.265 | 20 (31.3) | 23 (35.9) | 0.708 |
| pTm size, mm ± SD | 42.3 ± 30 | 31.4 ± 18.9 | 0.002 | 33.2 ± 23.1 | 30.2 ± 16.3 | 0.696 |
| yp tumor stage, n (%) | <0.001 | 0.488 | ||||
| T0 | 14 (10.9) | 11 (14.3) | 8 (12.5) | 10 (15.6) | ||
| T1 | 23 (18) | 33 (42.8) | 18 (28.1) | 25 (39.1) | ||
| T2 | 34 (26.5) | 16 (20.8) | 16 (25) | 14 (21.9) | ||
| T3 | 37 (29) | 13 (16.9) | 15 (23.4) | 12 (18.7) | ||
| T4 | 20 (15.6) | 4 (5.2) | 7 (11) | 3 (4.7) | ||
| yp nodal stage, n (%) | 0.013 | 0.227 | ||||
| N0 | 76 (59.3) | 55 (71.4) | 30 (46.9) | 46 (71.8) | ||
| N1 | 27 (21.1) | 12 (15.6) | 16 (25) | 10 (15.6) | ||
| N2 | 25 (19.5) | 10 (12.9) | 18 (28.1) | 8 (12.5) | ||
| Histology | 0.910 | 0.983 | ||||
| Adenocarcinoma | 76 (59.4) | 48 (62.4) | 38 (59.4) | 37 (57.8) | ||
| Squamous cell | 47 (36.7) | 26 (33.8) | 24(37.5) | 25 (39.1) | ||
| Other | 5 (3.9) | 3 (3.8) | 2 (3.1) | 2 (3.1) | ||
| Lymph nodes, mean ± SD | ||||||
| Total stations | 5 ± 1.9 | 5.5 ± 1.6 | 0.078 | 4.8 ± 1.6 | 5.9 ± 1.7 | 0.011 |
| Total lymph nodes | 10.7 ± 6.7 | 12.2 ± 5.1 | 0.400 | 11.5 ± 6.3 | 12.5 ± 5.3 | 0.219 |
| Completeness of resection, n (%) | ||||||
| R0 | 105 (82) | 73 (94.8) | 0.012 | 58 (90.6) | 60 (93.7) | 0.443 |
VATS: Video-assisted thoracoscopic surgery; SD: standard deviation. p values in bold are statistically significant.